HELP
Cybin Inc. Common Stock
1W: +0.0%
1M: -35.5%
3M: -33.8%
YTD: -42.6%
$4.75
+0.24 (+5.32%)
After Hours: $4.97 (+0.22, +4.74%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$237.0M
52W Range4.52-9.83
Volume697,856
Avg Volume835,691
Beta0.88
Dividend—
Analyst Ratings
Company Info
CEOMichael F. Cola
Employees50
SectorHealthcare
IndustryBiotechnology
IPO Date2019-09-13
Websitecybin.com
100 King Street West
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc. Common Stock
Clinical-stage biopharmaceutical company developing psychedelic-based therapeutics including CYB003 (deuterated psilocybin analog) for major depressive disorder and CYB004 (deuterated DMT) for generalized anxiety disorder
Latest News
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
12 Health Care Stocks Moving In Thursday's Intraday Session
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus posts mid-stage trial data for anxiety disorder therapy
Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise
Recent Insider Trades
No insider trades found